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III ABBREVIATIONS 
 
ABCB1  Gene sequence that codes P-gp 
AUC  Area under the time-concentration curve 
AUC0-12  Area under the time-concentration curve between  
  C0 and 12 hours post dose. 
AUC0-4  Area under the time-concentration curve between  
  C0 and 4 hours post dose. 
C0  Concentration prior to dose (through levels) 
C2  Concentration 2 hours post dose 
CI  Confidence interval 
CL   Apparent clearance 
Cmax   Maximum concentration of drug 
CP   Cyclophilin 
CRCL   Creatinine clearance 
CsA   Ciclosporin A 
CV   Coefficient of Variation 
CYP   Cytochrom P-450  
F  Bioavailability 
GOF  Goodness of fit 
i.v.  Intravenous 
IL-2   Interleukin-2 
IPRED  Individual predicted concentrations 
ka   Absorption rate constant 
ktr Transfer rate constant between the sequential compartments in the 
Erlang model 
MAP   Maximum a posteriori probability 
MAPE   Mean absolute prediction error 
MPE   Mean prediction error  
NFAT   Nuclear factor of activated T-lymphocytes 
OBS   Observed concentrations 
OFV    Objective function value  
p.o.   Per oral 
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P-gp   P-glycoprotein 
PRED   Predicted concentrations 
Q   Intercompartment clearance  
r   Coefficient of correlation 
r2   Coefficient of determination 
RBC   Reed blood cells 
RES   Residual error (OBS-PRED) 
SD   Standard deviation 
STS  Standard two-stage  
TDM   Therapeutic drug monitoring  
T-lymphocytes  Thymus lymphocytes 
Vc   Distribution volume in central compartment 
Vd   Apparent volume of distribution 
Vp   Distribution volume in peripheral compartment 
WRES Weighted residual error (RES expressed in fractions of population SD 
units)  
WT   Weight 
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IV ABSTRACT 
 
Background 
Ciclosporin A (CsA) is an important part of the immunosuppressive regimen in the treatment 
of renal transplant patients. CsA is typified by a great inter- and intraindividual 
pharmacokinetic variability, and narrow therapeutic window. Concentrations over the 
therapeutic window are associated with serious side effects, while concentrations under the 
therapeutic window are associated with risk of organ rejection. Therapeutic drug monitoring 
of CsA is therefore necessary. 
 
A pharmacokinetic population model predicts individual pharmacokinetic parameters not only 
based on patient observations, but also upon population data. The large pharmacokinetic 
variability of CsA seen in the population as well as significant patient demographics are 
implemented in such a model. A pharmacokinetic population model of CsA can therefore be a 
valuable tool used to optimize CsA dosing. The purpose of this study was to develop a 
pharmacokinetic population model for CsA. 
 
Methods 
Twelve hour concentration-time profiles of CsA from 17 renal transplant recipients were used 
to develop a pharmacokinetic population model using the nonlinear mixed effect approach as 
implemented in NONMEM. Different compartment models and especially different 
absorption processes were examined in order to find the best pharmacokinetic population 
model for CsA. Influence of covariates on the pharmacokinetic parameters was examined in 
accordance with traditional methods. The complete model was validated using both internal 
and external methods.  
 
Results 
A 2-compartment model with Erlang distribution as an absorption process was found to 
describe the pharmacokinetic data best. For the Erlang distribution, the optimal number of lag 
compartments placed upstream to the central compartment was six. Among the different 
covariates investigated, only age had a significant influence on the estimation of clearance.  
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The internal validation process found no individuals with large influence on the 
pharmacokinetic parameters and the model showed great robustness. In addition, the 
population model was able to predict individual AUC0-12 in patients excluded from the dataset 
using limited samplings points within the absorption phase. 
 
An external validation in 10 new renal transplant recipients showed that the pharmacokinetic 
population model also could predict individual AUC0-12 in an external population with same 
accuracy as in the internal validation process. 
 
Conclusion 
A 2-compartment model with Erlang distribution as an absorption process and age as a 
covariate on clearance described the CsA data best. This population model provides a good 
basis for the development of a model that can serve as a Bayesian prior when designing 
dosing regimens in new kidney transplant patients.  
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1 INTRODUCTION 
1.1 POPULATION PHARMACOKINETICS 
1.1.1 Introduction 
Population pharmacokinetics is an approach to quantify determinants of drug concentrations 
in a population of patients [1]. It can be defined as the study of variability in plasma drug 
concentrations among individuals representative for the target population group receiving the 
drug [2]. The use of population approaches for doing pharmacokinetic analyses has increased 
during the last 15 years [3]. 
 
In contrast to traditional pharmacokinetic analyses, the population approach encompasses 
some important features. Population pharmacokinetics seeks to obtain relevant 
pharmacokinetic information in patients who are representative of the target population. In 
addition it identifies and quantifies the sources of variability that contributes to differences 
between expectations and outcome. The variability is categorized as interindividual and 
residual [4, 5].  
 
Interindividual variability is the biological variability that exists between subjects. Searching 
for covariates that can account for some of the interindividual variability is another important 
feature of population pharmacokinetics. Covariates can be patient demographic features such 
as age, gender and body weight, environmental factors, genetic phenotypes, drug-drug 
interactions and physiologic factors such as renal impairment [4, 5].  
 
Residual variability is variability due to errors in concentration measurements, 
misspecifications of the model, inexplicable day-to-day or week-to-week variability (i.e. 
interoccasion variability) and intraindividual variability. Intraindividual variability is 
differences between the predictions of the model for the individual and the measured 
observations. Population pharmacokinetics also has the important feature of quantitatively 
estimate the residual variability in the patient population, which may give important 
information regarding drug efficacy and safety [4, 5].  
 
Population pharmacokinetics is often used in both drug development and individual dosing 
regimens. In drug development, population pharmacokinetics can help designing dosing 
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guidelines [6]. The approach is recommended in the US Food and Drug Administration 
(FDA) guidance for Industry as part of the drug development process [7]. For individual 
dosing regimens, population pharmacokinetics is useful in Bayesian approaches for estimation 
of individual pharmacokinetic parameters used in therapeutic drug monitoring [8]. In general, 
population pharmacokinetics is especially useful when working with drugs that have narrow 
therapeutic window and show large pharmacokinetic variability.  
 
Pharmacokinetic analyses can be model-dependent or -independent. Non-compartment 
approaches are model independent, which means that no assumption is made of any specific 
compartment model. Model independent analyses are often used to calculate basic 
pharmacokinetic parameters, which can be used as primary estimates in the population 
models. Model dependent analyses are often a more accurate physiological description of the 
data, where the models represent the body as a system of compartments.  
 
1.1.2 The concept of compartments 
In pharmacokinetic population modeling the body can be described in terms of compartments. 
A compartment is not a real physiologic or anatomic region. It represents a tissue or group of 
tissues that have similar blood flow and drug affinity. Within each compartment the drug is 
presumed to be uniformly distributed and to reach distribution equilibrium immediately [9].  
 
The simplest pharmacokinetic model consists of one compartment, which assumes that 
changes in the plasma level of a drug reflect proportional fast changes in tissue drug level [9]. 
However, not every drug equilibrates rapidly throughout the body as assumed for a one-
compartment model. In multicompartment models the drug distributes into the central 
compartment and one or more tissue/peripheral compartments. The central compartment 
represents the blood, extracellular fluid and highly perfused tissues that rapidly equilibrate 
with the drug. The tissue/peripheral compartment represents tissues where the drug 
equilibrates less rapidly [9]. 
 
The number of compartments required to describe the distribution of the drug equals the 
number of exponential terms needed to describe the plasma concentration-time curve [10]. 
Thus, a 2-compartment model is needed when the plasma concentrations are best fitted with a 
bi-exponential equation.  
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The pharmacokinetic parameters can all be part of the compartment model, as indicated in 
figure 1. The rate constants for the transfer between compartments are referred to as micro 
constants or transfer constants. Elimination is often assumed to occur from the central 
compartment, since the major sites of elimination are the kidney and the liver that are highly 
perfused with blood, and hence most often exerts fast distribution equilibrium. If the drug is 
eliminated at a constant rate, which means that the fractional rate of decline (∆C/∆t versus C) 
increases with time, the elimination kinetic is called zero order. In contrast, if the fractional 
rate of decline is constant, the elimination is assumed to be first order [10]. 
 
When the drug is administrated extravascularly, absorption is characterized by an absorption 
rate constant, ka, and a corresponding absorption half-life. The absorption, like elimination, 
can occur with zero or first order kinetics [10]. 
 
 
Figure 1: 2-compartment model with extravascular administration. The drug is absorbed inversely from 
compartment 1 into compartment 2, distributes between compartment 2 and 3 and is eliminated from 
compartment 2.  
Ka: absorption rate constant, Vc: distributjion volume in central compartment, CL: apparent clearance, Vp: 
distribution volume peripheral compartment, Q: intercompartment clearance, k20: elimination constant from 
compartment 2, k23, k32: rate constant between the compartments indicated. 
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1.2 MODELING APPROACHES 
Modeling approaches are either parametric or nonparametric. Parametric models have 
continuous parameter distribution, and the distribution is assumed to be either normal or 
lognormal. The parametric methods obtain means and standard deviations (SD) of the 
parameters, and correlations between them [11]. Nonparametric methods have no assumptions 
about the shape of the parameter distribution, which mean that no specific parameters such as 
means and SDs are used to describe the distribution of the parameters within a population a 
priori. The shape of the distribution is instead exclusively determined from the population 
raw data [12].  
 
The two most common methods for doing population pharmacokinetic analysis is the standard 
2-stage (STS) approach and the nonlinear mixed-effects approach, which are both parametric 
methods [11]. 
 
1.2.1 Standard 2-stage (STS) approach  
The standard 2-stage (STS) approach is the traditional method based on data-rich situations. 
The first stage involves estimation of individual pharmacokinetic parameters (and the 
correlations between them), using a method such as weighted nonlinear least squares. In the 
second stage the individual measurements are used to calculate the population mean and SD 
[11, 12].  
 
STS has the disadvantages of requiring at least one serum concentration data point for each 
parameter to be estimated, and does not consider variance of point estimates [11, 12]. STS 
gives poor predictions of parameters in situations with sparse data. However, this method is 
easy to implement and quick to run. 
 
1.2.2 Nonlinear mixed-effects approach (1-stage approach) 
The nonlinear mixed-effects approach considers the population sample, rather than the 
individual, as a unit for estimation of the distribution of parameters and the covariance and 
correlations between them [13]. It is called a 1-stage approach since all data of all individuals 
are analyzed at once. This method also works with only one measurement per patient [11, 12], 
and takes the variability within and between the individuals into account [13]. Other 
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advantages of the nonlinear mixed-effects method over STS are that it finds the best set of 
parameters and one can perform formal testing of covariates. However, it has the 
disadvantages of being more difficult to implement and slower to run compared to STS.  
 
The first true nonlinear mixed-effects modeling program introduced was NONMEM. See 
section 1.3.  
 
1.2.3 Bayesian procedure 
Bayesian procedure is a common method to estimate a patients own particular set of 
parameters [8], where the focus is moved from the typical patient to view the patient as 
unique. The results of a population analysis provide information to estimate an individualized 
dosing regimen, based on expected mean values of the parameters and estimates of the 
variability [1]. This approach balances the uncertainty in the individual parameter against 
uncertainty in the observations; the posterior are highly influenced of the probability that the 
prior is true. 
 
 
1.3 NONMEM 
1.3.1 Introduction  
A general approach to use patient data to account for some of the pharmacokinetic 
/pharmacodynamic variability among a patient group was introduced as early as 1972 by 
Sheiner et al. [14]. They suggested using non-linear mixed effects regression models to 
quantify inter- and intraindividual variability. The concept developed further into a computer 
program, NONMEM, which was first released in the early 1980s by Lewis Sheiner and Stuart 
Beal [15]. Besides being the oldest, NONMEM is probably the most widely used population 
analyse program today [16].  
  
NONMEM uses several building blocks to develop a mathematical representation (model) of 
experimental data arising from an unknown underlying process. One building block is the 
structural model that describes the basics of the process being examined. Other building 
blocks describe the random effects [15]. See sections 1.3.2 and 1.3.3.  
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1.3.2 Fixed effects in NONMEM 
The structural part of the model contains measurable population parameters and known 
patient characteristics. This is the explained part of the model [1]. Fixed effects are the 
population parameters, which in NONMEM are called theta (θ). The thetas define the average 
value for the population parameters, such as CL and Vd, and/or the average relationship 
between the population parameters and patient cofactors, such as weight and renal function 
[15]. 
 
1.3.3 Random effects in NONMEM 
NONMEM estimates the distribution of the random effects, which is typically normal with a 
mean zero and a variance. The building block for interindividual variability in NONMEM is 
eta (η) with a variance called omega squared (ω2). The building block for intraindividual 
variability in NONMEM is epsilon (ε) with a variance called sigma squared (σ2) [15].  
 
 
Interindividual variability: ),0( 2ωη N=            (1)               
Intraindividual variability: ),0( 2σε N=            (2) 
 
 
Random effects are implemented in NONMEM by using variance models. The most common 
variance models are additive, proportional and log normal. These models are applied to both 
inter- and intraindividual variability [15].  
  
Table 1: Variance models for random effects. 
Additive variance model Value = Predicted + Error 
Proportional variance model Value = Predicted * (1+Error) 
Log normal model Value = Predicted * Exp (Error) 
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1.3.4 Maximum Likelihood Estimation 
NONMEM uses maximum likelihood estimation when calculating the objective function 
value (OFV). OFV is an indication of how likely the present observations would have been 
observed, given that the model is true. NONMEM maximizes likelihood by minimizing -2 log 
likelihood [15]. 
 
The probability/likelihood of one observation is given by: 
 
( )221 ˆ2
2
1
2
-  Y YL =   e σπσ
−                            (3) 
 
Where Y is the measured observation, Ŷ is the prediction of that observation by the model 
and σ2 is the variance of the model. When expanding this to n observations and using -2 log 
instead of just L, one get the -2 log likelihood equation: 
 
( ) ( ) ( )
2
2
2
1
ˆ
2 log( ) log 2 log
n i i
i
i i
Y Y
L  = n   π σ σ=
⎛ ⎞−⎜ ⎟− + +⎜ ⎟⎜ ⎟⎝ ⎠
∑                 (4) 
 
 
The maximum likelihood principle states that one should choose those parameter estimates 
that correspond to the maximum of this likelihood function. This is because these particular 
parameter estimates render the observed data most probable to be “true” [17]. However, the 
best model is not necessarily the model with the lowest OFV, and different datasets can not 
compare OFV in absolute terms. A complex model with the lowest OFV always has to be 
justified with significant better fit of the data. Otherwise a more simple and faster model is 
preferred, especially if the model is to be used in clinical practise. 
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1.4 CICLOSPORIN A  
1.4.1 Introduction 
Ciclosporin A (CsA) is a lipophilic cyclic polypeptide containing 11 amino acids. It was 
isolated for the first time from the fungus Toly pocladium inflatum found in Hardangervidda. 
CsA’s immunosuppressive properties were discovered in 1972 [18], and was introduced into 
the marked as an immunosuppressive agent in the beginning of the 1980s [19]. 
 
CsA has been an important immunosuppressive agent in clinical practice since its introduction 
[19]. CsA led to an improvement in transplant graft outcome [20, 21], and improved the 
ability to transplant hearts [22]. However, CsA treatment is also associated with serious side 
effects such as nephrotoxicity, hypertension, dyslipidemia and development of diabetes [23-
26]. Due to the facts that CsA has a narrow therapeutic window and displays extensive inter- 
and intravariability in the pharmacokinetics (figure 2), routine therapeutic drug monitoring of 
CsA is necessary [19, 27], and the use of a population model would probably be of great 
value.  
Concentration-time curves for CsA
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Figure 2: Interindividual variability. 
Interindividual variability within the kidney transplant patients used to build the pharmacokinetic population 
model in this thesis (n=17). 
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1.4.2 Mode of action 
The mechanism of the immunosuppressive action results primarily from a selective 
suppression of T-lymphocyte activation. CsA inhibits the phosphatase activity of calcineruin 
via formation with cyclophilin, an intracellular protein in T-lymphocytes. This action prevents 
translocation of the nuclear factor of activated T-lymphocytes (NFAT), which is necessary for 
transcription of lymphokine genes, most notably the major T-lymphocyte growth factor 
interleukin-2 (IL-2) [28]. Thus, administration of CsA leads to blockage of transcription of 
lymphokine genes, which are essential for the differentiation and proliferation of T-
lymphocytes.  
 
1.4.3 Absorption 
The absorption of CsA after oral administration is unpredictable and shows large interpatient 
variability, and is characterized by a lag phase followed by rapid absorption. The site of 
absorption is predominantly the small intestine [29]. Due to its lipophilicity the absorption is 
dependent of bile flow, but is also affected by gut motility, food and time after transplantation 
[30]. With the conventional oral formulation of CsA (Sandimmun®), the bioavailability 
ranges from 1% to 89% [30]. A microemulsified formulation of CsA (Sandimmun Neoral®) 
improved the bioavailability and reduced the variability of gastrointestinal absorption [31]. 
This formulation has been used since mid 1990’s. A higher correlation between CsA dose and 
AUC has been shown with Sandimmun Neoral® compared to the conventional formulation 
[32]. However, there is still a large variation in the absorption of CsA.  
 
1.4.4 Distribution 
CsA is highly distributed to extravascular tissues, and has high affinity to blood cells and 
plasma components. Due to the lipophilic nature of CsA, the drug accumulates predominately 
in fat-rich organs such as liver, adipose tissue and lymph nodes [33]. About 50% of CsA in 
blood is bound to erythrocytes, 15% to leukocytes and 33% to plasma proteins and 
lipoproteins. In the plasma fraction, lipoproteins are the major complexing constituents for 
CsA [34]. The distribution of CsA in erythrocytes is dependent on temperature [35] and 
concentration [36], and may also be affected by patients’ hematocrit [37] and lipoprotein 
status [38, 39]. Whole blood is therefore the preferred matrix for therapeutic drug monitoring 
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of total CsA. In solid organ allografts Vd at steady state after intravenous administration has 
been reported to be between 3 to 5 L/kg [26].  
 
1.4.5 Elimination/metabolism 
Elimination of CsA is primarily via metabolism in the liver and the small intestine followed 
by excretion of metabolites in the bile (figure 3) [30]. Only 6% of administrated dose is 
eliminated by the kidney, with 0.1% excreted unchanged [26].  
 
CsA is extensively metabolised to more than 30 metabolites by the cytochrome P-450 (CYP) 
3A enzyme system [40]. CYP3A4 is the prominent enzyme in this subfamily [41], and 
accounts for about 80% of CsA metabolism [42]. Other isoenzymes, like CYP3A3 and 
CYP3A5, are also involved in the metabolism of CsA [43]. The importance and significance 
of the metabolites in terms of immunosuppressive activity and toxicity is not well-defined. 
However, there are works that indicate a correlation between blood concentrations of 
metabolites and nephrotoxicity, especially secondary metabolites like AM19 and AM1c9 [44, 
45]. Furthermore, a study by Dai et al. demonstrated that CYP3A5 polymorphism has an 
impact on the formation of secondary metabolites. More AM19 and AM1c9 were formed with 
liver and kidney microsomes with a CYP3A5*1/*3 genotype, compared to those with a 
CYP3A5*3/*3 genotype, particularly in kidneys carrying the wild-type CYP3A5*1/*1 [46]. 
 
INTRODUCTION 
   
 
19 
 
Figure 3: Overview of the distribution and elimination of CsA with metabolites. 
CsA: ciclosporin A, CP: cyclophilin, RBC: red blood cells, p.o.: per oral, i.v.: intravenous.  
Based on figure from Christians et al. [47]. 
 
 
1.4.6 P-glycoprotein (P-gp) 
CsA is both a substrate and an inhibitor of the ATP-driven efflux pump P-glycoprotein (P-gp) 
[48]. P-gp is encoded by the ABCB1 gene and is expressed in several locations in the body, 
including T-lymphocytes [49]. P-gp transports CsA out of T-lymphocytes, and the expression 
of P-gp could therefore affect its pharmacodynamic effect. An up-regulation of P-gp in T-
lymphocytes after renal transplantation [50], and in CsA-resistant patients [51] has been 
demonstrated. Measurements of intracellular CsA concentrations in T-lymphocytes could 
therefore be an important factor with regards to efficacy. 
 
P-gp is expressed in gut epitel cells, and some data suggest that the high unpredictability in 
CsA absorption found in vivo is associated with level of intestinal P-pg [52]. Variability in P-
gp expression can therefore also be important with regards to bioavailability. 
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1.4.7 Therapeutic drug monitoring (TDM)  
Historically, trough levels (C0) were used to monitor CsA therapy. However, studies have 
shown that C0 is a poor indicator of clinical outcome and total drug exposure [53]. AUC0-12 is 
a better predictor of outcome [54]. However, AUC0-12 can not be used in clinical practice 
because it is time consuming, expensive and inconvenient. Attention became focused on 
sampling during the first four hours (AUC0-4), the absorption phase, where the variability is at 
its maximum. AUC0-4 was shown to correlate well with AUC0-12, and was predictive for 
clinical outcome (both toxicity and rejection) [55]. It was further shown that the concentration 
2 hours post dose (C2) was the single point measurement that correlated best with AUC0-4 in 
renal transplant recipients [56]. Besides being a practical and convenient method in clinical 
settings, C2 monitoring is considered to be a feasible TDM method today that also give lower 
acute rejections frequencies [57, 58]. However, the clinical benefit of C0 over C2 monitoring 
has still not been fully proven [59]. 
 
1.4.8 Pharmacokinetic population models of CsA in the literature 
There are several published pharmacokinetic population models for CsA in renal transplant 
recipients using NONMEM in the literature. The choice of compartment model varies; one 
[60, 61]-, two- [62, 63] and three [64]- compartment models have been used to fit CsA whole 
blood concentrations. Both zero [62] and [60] first order kinetics are used to describe the 
absorption phase. A delay in the absorption of CsA is often observed. For the models that 
includes a delay function in the absorption phase both a lag-time parameter [62, 65] and 
Erlang distribution/gamma model [63, 66, 67] have been used. Some published models do not 
account for the delayed absorption [64, 68]. However, few of the population models have 
been externally validated. 
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1.5 AIMS 
The purpose of this thesis was to develop a pharmacokinetic population model for CsA using 
NONMEM. The specific aims were: 
1. Examine different compartment models with different absorptions profiles, in order to 
find the pharmacokinetic population model that describes the data best. 
2. Screen for significant covariates that can reduce interindividual variability in the 
pharmacokinetic parameters. 
3. Validate the final pharmacokinetic population model, with internal and external 
methods.
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2 MATERIALS AND METHODS 
2.1 PATIENTS 
Twelve hour concentration profiles of CsA, performed within three months after 
transplantation, from 17 kidney transplant recipients were used in this thesis to develop a 
pharmacokinetic population model. These 17 patients participated in two different clinical 
trials; the MIMPARA study [69] and the SUPER-CsA study [70]. 
 
The MIMPARA study is an interaction-study including 14 renal transplant patients with 
stable renal function, of which 8 patients were treated with CsA. These 8 patients had one full 
twelve hour concentration profile performed. The SUPER-CsA study is a single centre 
prospective pilot study including 20 kidney transplant patients, all on a CsA-based 
immunosuppressive regimen. The patients were included within two weeks post transplant 
and followed for three months. 9 patients had one full twelve hour pharmacokinetic profile 
performed. The patients with full twelve hour concentration profiles for CsA performed from 
these two studies were used to develop a pharmacokinetic population model.  
 
The main characteristics of the patients studied in this thesis are listed in table 2. 
 
MATERIALS AND METHODS 
   
 
23 
Table 2: Patient demographics. 
 
 
2.2 MODEL BUILDING  
The pharmacokinetic population analyses were performed using the nonlinear mixed effect 
approach as implemented in NONMEM (version VI) [15]. Different compartment models 
were examined in order to find the best pharmacokinetic population model for CsA. One- 
two- and three-compartment models were tested, applying both first- and zero order 
absorption kinetics. The models were in addition tested with a lag-time parameter in the 
absorption phase. Erlang transit times for drug passage through the compartments were also 
examined, which can be used to describe lagged absorption processes. When using Erlang 
distribution as an absorption model, it is defined as the analytic solution for a linear chain of 
identical compartments placed upstream to the central compartment and connected by 
Patient 
ID 
CsA 
morning-
dose (mg) 
Sex 
(F/M) 
Age 
(yrs) 
Weight 
(kg) 
Height 
(cm) 
Serum 
creatinin 
(µmol/L)
* 
Steroid 
dose 
(mg) 
Post trans-
plantation 
period  
(weeks) 
Diabetes
Super 
CsA 
study 
                  
7 100 F 60 70 165 155 10 9.0   
8 225 M 59 90 185 95 20 4.1   
9 200 F 33 76 180 144 20 7.6   
10 150 M 35 68 185 184 15 4.6   
11 200 M 52 75 188 110 20 4.4   
12 225 M 67 97 181 133 15 4.3   
14 125 F 60 69 172 76 15 6.3 X 
18 125 M 74 74 164 148 20 3.1   
19 350 M 52 80 176 142 20 2.1 X 
MIM- 
PARA 
study 
                
30 150 M 25 92 182 131 10 9.3   
31 125 F 61 78 170 98 20 10.4   
32 150 M 59 91 179 103 20 9.0 X 
33 175 F 68 78 156 92 20 3.0 X 
34 125 F 69 86 164 109 15 6.9   
35 250 M 23 80 180 82 15 4.0   
36 125 M 52 86 189 127 20 3.0   
37 125 M 59 86 189 128 20 3.3   
Mean 172   53 81 177 121 17 5.6   
SD 64  15 9 10 29 4 2.6  
*Calculated with Nankivell formula; GFR (ml/min)= 6.7/SCr (mmol/L) + weight (kg)/4 – urea (mmol/L)/2 – 
100/height2 (m) + [35(man) eller 25(female)]  
SD:standard deviation, F:femal, M:man 
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identical rate constants (ktr) [71]. OFV (objective function value) in NONMEM was used to 
optimize the number of lag-compartments (a) in the Erlang model (figure 4). 
 
ktr ktr ktr ktr ktr
Vc/F Vp/F
Q/F
CL/Fa
ktr
 
Figure 4: Erlang transit times for drug passage.  
 
 
The models were parameterized in terms of volume of distribution (Vd) and clearance (CL), 
with an absorption rate constant (ka). Vd and CL were represented as ratio to the unknown 
bioavailability (F), since CsA was administered orally.  
 
The interindividual variability was described by an exponential error model, while the 
residual error was modeled using additive, proportional or combined error models.  
 
 
Comparison between the tested models was based on:  
 Objective function value (OFV) 
The change in OFV was used to compare different models tested. If a new tested model 
produces a decrease in OFV ≥ 3.84, the new model gives a significant (p<0.05) better fit of 
the observed data. 
 
 Goodness-of-Fit (GOF): 
GOF plots give a basic internal evaluation of a model. Potential bias or problems in the 
structural model and/or the random effects models can be detected. GOF plots that were 
evaluated were ratio population predictions (PRED)/observation (OBS) versus time, ratio 
individual population predictions (IPRED)/observation (OBS) versus time, OBS versus PRED 
and IPRED, population residuals (RES) and population weighted residuals (WRES) versus 
PRED and WRES versus time, PRED and IPRED. 
 
 
MATERIALS AND METHODS 
   
 
25 
 Parameters estimates and variability 
The likelihood of the estimated parameter values and the magnitude of interindividual 
variability and residual error were considered. 
 
The interpatient variability in the pharmacokinetic parameters was estimated by calculating 
%CV (coefficient of variation). When using an exponential error model for the variability, 
%CV is determined by taking the square root of the eta value for that parameter and 
multiplying by 100. The intrapatient variability was also estimated by calculating %CV for 
the proportional error model, but given as absolute variability when using an additive error 
model. Additive variability is calculated by taking the square root of the eta value for that 
parameter.  
 
 
2.3  COVARIATE ANALYSIS 
The analysis for influence of covariates on the pharmacokinetic parameters was performed in 
accordance with traditional methods [72-74]. First graphical analyses were conducted to study 
the relationship between each parameter and covariate according to the method described by 
Maitre et al. [74]. The demographic parameters of interest (x-axis) were plotted against the 
individual estimated pharmacokinetic parameters (y-axis). The individual estimated 
pharmacokinetic parameters were obtained using the “posthoc” subroutine in NONMEM, and 
the statistic program R was used to create the scatter plots. From the scatter plots covariates 
that correlate with the pharmacokinetic parameters can be identified. Correlations seen in the 
scatter plots have the possibility of being clinically relevant, and were tested in the next step. 
Weak correlations in the scatter plots are probably not applicable for this model, and were not 
tested any further. 
 
The influence of 7 cofactors was studied: weight (kg), creatinine clearance (mL/min), age 
(years), height (cm), gender, post-transplantation period (weeks) and steroid dose at the 
pharmacokinetic day (mg/day).  
 
The demographic factors showing a correlation with a pharmacokinetic parameter were 
further tested using the “forward inclusion-backward elimination” method [72-74]. Each of 
the covariates found in the first step was introduced separately into the structural model to 
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asses its impact on the pharmacokinetic parameters. Covariates were modeled as being both 
proportional and linear to the typical parameter value. The covariates centred on the mean 
covariate value were also tested, exemplified by the typical value of distribution volume 
(TVV) and bodyweight (WT): 
 
Proportional model:  ))( (  ∗ = 1ΕΤΑEXP*WTθTVV 1            (5) 
Linear model   
(mean centred):   ))( (  ∗ )]−( ∗+= 1ΕΤΑEXPmedianWTWTθ [θ TVV 21      (6) 
 
The likelihood ratio was used to test the effect of each covariate on the pharmacokinetic 
parameters in this next step. A covariate was selected significant if it produced a decrease in 
OFV ≥ 3.84 (p<0.05) from the covariate free model [73]. All the significant covariates were 
then added simultaneously into the covariate free model. The OFV for this model, including 
all the statistically significant covariate-parameters relationship, was noted. Thereafter, in a 
backward deletion strategy, each covariate was taken out of the model independently from the 
full model. An increase in OFV ≥ 6.6 (p<0.01) was required to consider the covariate as 
significant and to keep it in the model [73]. Finally, all the significant covariates were 
introduced into a final model.  
 
It is well known that some patients show a very slow absorption profile, and the relationship 
between slow absorption profile and the presence of diabetes was tested [75]. Therefore, slow 
absorption profile was first considered to be a binary covariate, using a FLAG function in 
NONMEM. The patients with diabetes were “flaged”, and NONMEM estimated a separate 
absorption constant (ka) for these patients. The change in OFV and GOF plots were used to 
evaluate whether this produced a better model. 
 
An another method was also used in order to account for two different absorption constants, 
without taking the conclusion the reason was diabetes. This was done by using the mixture 
function in NONMEM [76]. This means that NONMEM will divide the population into the 
number of subpopulation decided beforehand, without deciding which patients are in which 
population in advance. Here two subpopulations with two different absorption constants were 
tested. In the same procedure, the change in OFV and GOF plots were used to evaluate 
whether this improved the model. 
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2.4 VALIDATION 
2.4.1 Posterior predictive check 
A posterior predictive check method [77] was chosen as an initial validation procedure. With 
this approach the compatibility of the data and model is assessed by comparing simulated 
concentrations with observed concentrations. Simulated concentrations were estimated via the 
simulation function in NONMEM. A dataset with significant covariates, doses and time 
measurements, but without the observed concentrations, was created. The estimation 
command in NONMEM was replaced by a simulation command ($SIMULATION), and the 
thetas, omegas and sigmas were fixed to the estimates from the final model. 100 simulations 
were performed. 
 
For each subject in each simulation, Cmax, Ctrough and AUC0-12 were calculated and compared 
with Cmax, Ctrough and AUC0-12 from the observed data. The mean values of the observed data 
were compared to 95% confidence interval (CI) limits from the simulated data. Paired statistic 
tests using SPSS were performed to determine whether the observed and simulated mean 
values were significant different. 
 
2.4.2 Jackknife estimation 
A Jackknife run was performed in order to find the confidence interval (CI) of the 
pharmacokinetic parameters. Each patient was in order excluded form the data set, which then 
gave 17 Jackknife datasets. These Jackknife datasets were examined in NONMEM using the 
final pharmacokinetic population model, producing a new set of estimates for the 
pharmacokinetic parameters. The pharmacokinetic estimates from the Jackknife datasets were 
tested for normality in SPSS, and a 95% CI were then calculated. 
  
A Jackknife run will also identify individuals that have large influence on the estimation of 
the values of the parameters. 
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2.4.3 Data splitting 
A data-splitting method was applied to confirm the robustness of the final model, and to 
determine the contribution of data from individuals in a subset group [78]. The full data set 
were divided into 10 subsets randomly. Each subset contained data from approximately 90% 
of the patients, and were examined in NONMEM using the final model. The 10 subset groups 
are presented in table 3. 
 
Table 3: Subset groups. 
Group Patient(s) 
excluded 
1 8  
2 30  
3 36  
4 11 19 
5 7 9 
6 10 12 
7 14 31 
8 35 37 
9 18 33 
10 32 34 
 
 
The parameter estimates determined from the subset analyses were compared in terms of the 
SD’s of the parameters in the full dataset.  
 
The OFV was also calculated by another NONMEM run for the full data set, but with the 
parameter estimates fixed at the estimates from the subset analyses. The OFVs obtained in 
this step were compared with the OFV from the full data set. 95% CI for the absolute 
difference in OFV is achieved if the absolute difference of these values from that of the final 
model is ≤ 3.84. 
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2.4.3.1 Predictive performance 
The NONMEM estimates from each of the 10 subsets were used to predict CsA 
concentrations in the remaining 10% of the patients’ data. 10 control files with initial 
estimates of theta, omega and sigma replaced by the estimates from the 10 subsets were 
created. The individual concentrations were estimated using the “posthoc” subroutine and 
with the $ESTIMATION command set to MAXEVAL = 0, which means that the estimation 
step will be omitted. A dataset with significant covariates and doses was created. The 
predictive performance was tested without any concentration measurements provided in the 
dataset, with one concentration at time 0 and 2 hours post-dose provided, with two 
concentrations at time 0 and 2 hours post-dose and time 1 and 2 hours post-dose provided and 
three blood samples at time 0, 1 and 2 hours post-dose and 0, 1 and 3 hours post-dose 
provided. The choices of time measurements was based on empiricism and the fact that 
AUC0-4 is a good predictor for clinical outcome [55]. 
 
Estimated AUC0-12 at the different time measurements given were compared with observed 
AUC0-12, calculated using the linear-trapezoidal method. To evaluate predictive performance, 
the mean percentage prediction error (%MPE) and the mean precentage absolute prediction 
error (%MAPE) were calculated. 
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Bias is estimated by mean prediction error (MPE) and the precision of the predictions is 
estimated by the mean absolute prediction error (MAPE). 
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2.4.4 External validation with Bayesian procedure 
The Bayesian approach was applied to an external group of 10 kidney transplant patients. 
These new patients participated in a different study were the pharmacokinetics in elderly were 
examined [79]. The main characteristics of the patients in the external group are presented in 
table 4.  
 
Table 4: Patient demographics in the external group. 
 
   
 
 
 
 
 
 
 
 
 
 
A MAP (maximum a posteriori) Bayesian estimator using the same time measurements as in 
the predictive check of the data splitting analyses were tested. The final pharmacokinetic 
population model was used to obtain Bayesian individual estimates of the pharmacokinetic 
parameters in the external validation set. Bayesian estimation was performed using the 
“posthoc” subroutine and with the $ESTIMATION command set to MAXEVAL = 0. 
 
Predictive performance was evaluated in same procedure as explained in section 2.4.3.1. 
 
 
 
 
 
 
 
 
 
 
 
Patient 
 ID 
CsA morning 
-dose (mg) 
Sex 
(F/M) 
Age 
(yrs)
A 225 M 28 
B 200 M 67 
C 275 M 29 
D 175 F 55 
E 150 M 78 
F 225 M 63 
G 175 M 64 
H 125 F 73 
I 300 M 48 
J 125 M 75 
Mean 198  58 
SD 59  18 
SD:standard deviation, F:femal, M:man 
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2.5 NON-POPULATION ANALYSES  
A non-compartmental analysis of the dataset was first performed. This was done by manual 
calculation in Excel. In addition a pharmacokinetic modeling analysis of the dataset using 
WinNonlin was performed. WinNonlin is a tool for nonlinear modeling. A 2-compartment 
model with first order absorption and a lag-time was chosen from the library in WinNonlin to 
fit the data. 
 
This was done in order to test for significant different estimates of CL and Vd between non-
compartment analysis, simple pharmacokinetic modeling and pharmacokinetic population 
modeling. 
 
 
2.6 STATISTICS 
When testing different models in NONMEM, the models were considered statistic different if 
p < 0.05 (corresponding to OFV ≥ 3.84). 
 
Statistic analyses were performed using SPSS for Windows (version 12). Normality was first 
assessed to determine which statistic analysis to apply. In the predictive check analysis, 
student’s t-test was used to assess differences between observed and simulated values for 
AUC0-12 and Cmax (normally distributed), and Wilcoxen matched pairs signed ranks test was 
used to assess differences between observed and simulated values for Cmin (not normally 
distributed) [80]. When testing for significant differences in the estimation of CL/F and Vd/F 
between non-compartment calculations, WinNonlin and NONMEM, one-way repeated 
measures ANOVA test was used to asses differences in the estimation of CL/F (normally 
distributed), and Friedman Test was used to asses differences in the estimation of Vd/F (not 
normally distributed) [80]. 
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3 RESULTS 
3.1 DIFFERENT COMPARTMENT MODELS WITH DIFFERENT ABSORPTION 
PROFILES 
 
The 2-compartment model with Erlang distribution in the absorption phase had the lowest 
OFV of all models tested (table 5). The residual variability was about the same for the 2-
compartment model with Erlang distribution, the 2-compartment model with lag-time and the 
3-compartment model with lag-time.  
 
Table 5: Comparison of different covariate free models tested for modeling CsA pharmacokinetics based on 
Objective Function Value (OFV) and residual variability. 
Model tested OFV Residual variability 
(Proportional/Additive) 
1-compartment with  
first order absorption 
2584 
 
39.50% 
 
1-compartment with first order  
absorption and a lag-time 
2510 
 
30.58% / 55.86 µg/L 
2-compartment with 
zero order absorption 
2571 37.95% 
 
2-compartment model with  
first order absorption 
2488 
 
31.00% 
 
2-compartment model with first order 
absorption and a lag-time 
2282 
 
13.08% / 37.42 µg/L 
3-compartment model with  
first order absorption 
2293 
 
13.67% / 35.50 µg/L 
2-compartment model with Erlang 
distribution as an absorption process 
2280 
 
13.53% / 37.55 µg/L 
 
 
The CL1/F estimates were similar between the different models, however the distribution 
volumes and absorption constants considerably differed between them (table 6).  
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Table 6: Pharmacokinetic parameter estimates in the different models tested. 
Model CL1/F 
(L/h) 
V1/F 
(L) 
CL2/F 
(L/h) 
V2/F 
(L) 
CL3/F 
(L/h) 
V3/F 
(L) 
Ka 
(h-1) 
Lagtime 
(hrs) 
1-compartment  20.6 117     1.92  
1-compartment 
with lag-time 
20.2 113     5.55 0.438 
2-compartment 
0. order 
absorption 
16.3 
 
1.00 64.1 78.0   0.320 0.300 
2-compartment 22.0 47.7 17.8 991   0.802  
2-compartment 
with lag-time 
21.4 27.4 22.8 337   1.03 0.454 
2-compartment 
with Erlang 
absorption 
21.8 58.8 23.1 245   7.90*  
3-compartment 
with lag-time 
21.4 50.9 10.5 32.3 12.8 5630 1.92 0.451 
*ktr (transfer rate constant between the sequential compartments) in the Erlang model 
CL1/F = apparent clearance, V1/F = volume of the central compartment, CL2/F = intercompartment  
clearance 1, V2/F = volume of peripheral compartment 1, CL3/F = intercompartment clearance 2, V3/F = 
volume of peripheral compartment 2, Ka = absorption rate constant 
 
 
For the 3 models with lowest OFV (2-compartment model with lag-time, 3-compartment 
model with lag-time and 2-compartment model with Erlang distribution) the predicted 
concentrations correlated generally well with the observed concentrations, as seen in figure 5. 
However, in the 2-compartment model with Erlang distribution in the absorption phase the 
parameter estimates were highly robust compared with the 2-compartment model with lag-
time and the 3-compartment model with lag-time. For these two models, the parameters were 
very sensitive for initial estimates. In the other compartment models examined, NONMEM 
was not able to predict the highest concentrations (figure 5). Moreover, the absorption phase 
was poorly described without accounting for a delay in absorption, as done with a lag-time 
parameter or Erlang transit time for drug passage.  
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Figure 5: Concentration-time curves for the different compartment models tested.  
Concentration (µg/L) is given at the y-axis and time (hrs) is given at the x-axis. Red lines are the concentrations 
predicted by NONMEM, and the green lines are the measured concentrations. The type of compartment model is 
indicated over the graph. 
Predicted concentrations 
Observed concentrations 
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For the Erlang model, the optimal number of sequential compartments placed upstream to the 
central compartment was six. Including one more sequential compartment did not lead to 
significant change in OFV (table 7).  
 
Table 7: Results for 2-compartment model with Erlang distribution as an absorption process with increasing 
number of sequential compartments. 
 CL /F (L/h) Vc/F (L) VP/F (L) Q/F (L/h) Ktr (h-1) OFV 
1 LAG 22.2 34.5 237 22.6 1.45 2402.50 
2 LAG 21.8 22.9 150 28.3 2.11 2338.90 
3 LAG 21.7 40.8 151 27.5 3.62 2310.53 
4 LAG 21.6 49.3 179 25.4 5.05 2293.03 
5 LAG 21.8 55.2 209 24.1 6.45 2284.06 
6 LAG 21.8 58.8 245 23.1 7.86 2280.00 
7 LAG 21.8 61.5 284 22.3 9.27 2279.14 
LAG = number of sequential compartments placed upstream to the central compartment ktr = transfer rate 
constant between the sequential compartments, CL/F = apparent clearance, VC/F = volume of the  
central compartment, Q/F = intercompartment clearance, VP/F = volume of peripheral compartment  
F = bioavailability 
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3.2 COVARIATE ANALYSIS 
3.2.1 Graphical analysis 
From the graphical analyses conducted, weight, age and creatinine clearance tended to 
correlate with some of the pharmacokinetic parameters (figure 6). These covariates were 
therefore tested further for their significance with the inclusion-deletion method. The other 
covariates tested had low coefficient of determination values (r2).  
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Figure 6: Graphical analysis. 
An extract of graphs for testing correlations between pharmacokinetic parameters and covariates.  
VC = volume of the central compartment, VP= volume of peripheral compartment, CL = apparent clearance, 
WT= weight, CRCL = creatinine clearance. 
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3.2.2 Inclusion-deletion method 
From the inclusion step, with weight as a covariate on VC/F a reduction in OFV of 1.58 was 
achived, however the OFV value did not change when modeling weight as a covariate on 
VP/F (table 8). A slightly reduction in OFV was also seen when modeling weight as a 
covariate on Q/F (∆OFV = 0.82). Creatine clearance (CRCL) as a covariate on CL/F gave a 
reduction in OFV of 0.88, in addition to a reduction in OFV of 0.96 when modeling CRCL as 
a covariate on VC/F. All these relationships were insignificant, and were therefore not tested 
further.  
 
Age as a covariate of CL/F gave a reduction in OFV of 5.62 in the inclusion step, which is 
significant. The relationship was CL/F = TVCL – θ * AGE where TVCL is the typical value 
of clearance, and θ had a mean value of 0.116. The interindividual variability of clearance was 
slightly reduced from 32.5% to 29.8%. However, the interindividual variability of VP/F was 
reduced from 110% to 95.6%. Since this was the only covariate that gave a statistically 
significant reduction in OFV by inclusion, the deletion step could not be performed.  
 
The relationship between diabetes and slow absorption profile were tested using a flag 
function. Including a flag function in the model did not give a better fit of the CsA data. Both 
the GOF plots and OFV (∆OFV = 0.7) were about the same as in the covariate free model. 
The estimated ktr for diabetics were 7.84, compared with 7.87 in non-diabetics.  
 
Including the mixture function for the absorption constant in the covariate-free model gave a 
significant reduction in OFV (∆OFV = -5.5) and better GOF plots. However, NONMEM 
placed only one patient in the subpopulation with slower absorptions profile. The impact of 
having two different absorption constants was therefore considered not to be clinically 
relevant.  
 
None of the other covariates induced statistically significant decrease in OFV, as can be seen 
from table 8. 
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Table 8: Changes in OFV due to inclusion of covariates; the inclusion step. 
∆ OFV    
CL/F VC/F VP/F Q/F Ktr 
WT  0.01 -1.58 0.00 -0.82   
CRCL -0.88 -0.96 0.00  0.01   
AGE -5.62  0.01 0.00  0.00   
MIXTURE     -4.44 
WT = weight, CRCL = creatinine clearance, CL/F = apparent clearance, VC/F = volume of the central 
compartment, VP/F = volume of peripheral compartment, Q/F = intercompartment clearance,  
ktr = transfer rate constant between the sequential compartments, F = bioavailability. 
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3.3 THE BEST PHARMACOKINETIC POPULATION MODEL 
The best pharmacokinetic population model found for the CsA dataset was a 2-compartment 
model with Erlang distribution in the absorptions phase and age as a covariate for clearance. 
 
3.3.1 Parameter estimates with variability 
The mean values of population parameters and the interindividual variability obtained in the 
2-compartment model with Erlang distribution are listed in table 9. 
 
Table 9: Pharmacokinetic parameters and interindividual variability in the final model. 
Parameter Ktr 
(h-1) 
CL/F 
(L/h) 
VC/F 
(L) 
Q/F 
(L/h) 
VP/F 
(L) 
Covariate 
Mean 7.84 28.1 58.8 23.1 215 0.116 
95% CI* 7.78-7.91 27.5-28.7 57.6-59.5 22.9-23.3 205-226 0.109-0.126
Interindividual 
variability (%CV) 
24.2 29.8 52.1 14.5 95.6  
*Calculated in section 3.4.2 
CI = confidence interval, CV = coefficient of variation, ktr = transfer rate constant between the sequential 
compartments, CL/F = apparent clearance, VC/F = volume of the central compartment, Q/F = 
intercompartment clearance,VP/F = volume of peripheral compartment, F = bioavailability. 
 
 
The residual error of the model (table 5) was 13.5% (proportional error model) and 37.6 µg/L 
(additive error model).  
 
3.3.2 Goodness-of-fit (GOF) plots 
The goodness-of-fit (GOF) plots presented in figure 7 showed no indication of model 
misspecification. The plots of ratio OBS/PRED versus time and ratio OBS/IPRED versus 
time showed no relevant bias over or under the value of 1, which is the value if PRED or 
IPRED is identical with OBS. The distribution of WRES as a function of sampling times and 
ID was homogeneous, and WRES were in an acceptable range. One WRES was >5, which 
can be an indication of an outlier. Moreover, the scatter plots of PRED and IPRED versus 
OBS did not show bias and the plots showed good correlations. The coefficient of 
determination (r2) was high for IPRED (r2=0.95).  
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Figure 7: GOF plots for the 2-compartment model with Erlang distribution. 
OBS = observed concentrations, PRED = predicted concentrations, IPRED = individual predicted 
concentrations, WRES = weighted residual error, ID = patient number. 
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3.3.3 Individual fits 
The final population model described the pharmacokinetic data of CsA well, as seen in the 
individual plots (appendix). Two of the best and worst fits are shown in figure 8. 
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Figure 8: The best and worst fits.  
ID 11 and 31 represents the best fits, and ID 10 and 19 represents the worst fits. The circles are the 
concentrations observed (CON), the green lines are the predicted concentrations (PRED) and the red lines are 
the individual predicted concentrations (IPRED). 
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3.3.4 Control file  
The control file for the final pharmacokinetic population model is presented in figure 9 below. 
 
 
 
 
$PROB Erlang distribution 6 lag; States the problem being solved 
 
$DATA Inputfil.txt; Name of dataset 
 
$INPUT ID AMT RATE TIME CON=DV MDV SS II CMT AGE ; Identifies columns in dataset 
;ID=patient ID, AMT= amount of drug administered (µg), RATE: route of administration, TIME= 
time of concentration measurement (hours), CON=concentrations measured (µg/L), DV=dependent 
value, MDV=missing data variable, SS=steady state, II:dose interval, CMT: defines in which 
compartment DV is observed, AGE=age of patient (years) 
 
$SUBROUTINE ADVAN5 SS5; Set up differential equation mode 
 
$MODEL COMP=(DEPOT,DEFDOSE) ; Defines the number of compartments 
    COMP=(DELA1) 
    COMP=(DELA2) 
    COMP=(DELA3) 
    COMP=(DELA4) 
    COMP=(DELA5) 
    COMP=(DELA6)            ; “Erlang” compartments 
    COMP=(CENTRAL,DEFOBS) ; Central compartment 
    COMP=(PERIPH)           ; Pheripheral compartment 
 
$PK ; Define basic pharmacokinetic parameters 
  K12=THETA(1)*EXP(ETA(1)) ; Rate constant between the delay compartments  
  K23=K12  
  K34=K12 
  K45=K12 
  K56=K12 
  K67=K12 
  K78=K12 
   
  CLTV=THETA(2)-THETA(6)*AGE ; Clearance depends on age 
  V8TV=THETA(3) 
  V9TV=THETA(4) 
  QTV=THETA(5) 
 
  CL=CLTV*EXP(ETA(2)) ; Clearance  
  V8=V8TV*EXP(ETA(3)) ; Central volume of distribution  
  V9=V9TV*EXP(ETA(4)) ; Pheriperal volume of distribution 
  Q=QTV*EXP(ETA(5)) ; Intercompartment clearance 
   
  K80=CL/V8 ; Micro constant between central compartment and out of the system 
  K89=Q/V8  ; Micro constant between central and peripheral compartment 
  K98=Q/V9  ; Micro constant between peripheral and central compartment 
   
  S8=V8     ; Scale for central compartment 
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Figure 9: Control file for the 2-compartment model with Erlang distribution to describe the absorption phase. 
Explanations are given after semicolon, and will not be recognised by NONMEM. 
 
 
 
$ERROR  
  IPRED=F 
  Y=F+F*ERR(1)+ERR(2) ; Additive and proportional residual error model 
 
$THETA ;  
 (1,7.8) ; K12 (B) 
 (10,22) ; Q/F 
 (10,58) ; V8 
 (10,244) ; V9 
 (10,23) ; CL/F 
 (0.001,0.05) ; age effect 
 
$OMEGA ; Variance of interindividual variability  
0.06 ; K12 
 
$OMEGA BLOCK(4) ; Variance of interindividual variability 
0.1                  ;CL 
0.02  0.1             ;V8  
0.02  0.02  0.1        ;V9 
0.02  0.02  0.02 0.1   ;Q 
 
$SIGMA 0.1 ; Variance of intraindividual variability, proportional error model 
$SIGMA 25 ; Variance of intraindividual variability additive error model  
 
$ESTIMATION SIG=3 MAX=9999 PRINT=1 METHOD=1 INTER POSTHOC 
;SIG=number of significant digits in the final parameter estimates  
;MAX= maximal number of iterations (function evalutions) before NONMEM gives up  
;PRINT=determines how often summaries of iterations are printed  
;METHOD: 0 when the FO estimation method is used, and 1 when the FOCE method is used. 
;INTER: required when using the FOCE method;  
;POSTHOC: optaines individual estimates of the parameters 
 
$COVARIANCE ; Requests that the covariance step be implemented (optional)  
 
$TABLE ID TIME DV IPRED 
    NOPRINT ONEHEADER FILE=table.txt; Prepare an output table of results 
 
$TABLE ID V8 V9 CL Q WT CRCL AGE SEX HT TXT STER ETA1 ETA2 ETA3 ETA4 
    FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
    ; Prepare an output table of results 
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3.4 MODEL VALIDATION 
3.4.1 Posterior predictive check 
The 95% confidence interval (CI) of Cmax, Ctrough and AUC0-12 from the posterior predictive 
check contained the true observations. Also paired statistic tests performed using SPSS 
showed no significant distinguish (p>0.18) between observed and simulated values of Cmax, 
Ctrough and AUC0-12 (table 10). 
 
Table 10: Results from posterior predictive check. 
 Observed values 
(mean) 
Simulated values 
(95% CI) 
P-value 
AUC0-12 (µg/L*h) 7671 6867-9567 0.435 
Ctrough (µg/L) 288 278-376 0.177 
Cmax (µg/L) 2090 1735-2477 0.950 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
   
 
45 
3.4.2 Jackknife 
The 95% CI for the pharmacokinetic parameters were calculated from the Jackknife estimates, 
and are presented in table 11. No individuals showed any significant influence on the 
pharmacokinetic parameters (table 11).  
 
Table 11: Pharmacokinetic parameter estimates from the Jackknife run of the 2-compartment model with Erlang 
distribution. 
  Patient excluded  
Covariate Final 
model 
7 8 9 10 11 12 14 18 19  
ktr 7.84 7.86 7.74 7.81 7.89 7.89 7.65 7.87 7.91 7.88  
CL/F 28.1 28.3 28.0 25.6 31.3 28.1 26.7 28.6 29.8 27.2  
VC/F 58.5 60.2 56.6 56.8 62.0 58.2 55.6 60.7 60.1 55.0  
Vp/F 215 188 202 203 233 251 191 242 216 202  
Q/F 23.1 23.4 23.4 22.8 23.6 23.3 23.2 23.2 23.7 22.8  
AGE effect 
on CL 
0.116 0.109 0.121 0.082 0.158 0.116 0.097 0.120 0.146 0.113  
  Patient excluded   
  30 31 32 33 34 35 36 37   
ktr  7.98 7.74 7.95 7.66 7.77 8.19 7.81 7.73   
CL/F  27.2 28.2 27.9 27.7 28.4 29.2 27.4 28.5   
VC/F  57.0 59.3 58.3 58.1 61.4 56.7 59.5 60.0   
Vp/F  203 199 246 227 230 188 203 245   
Q/F  23.4 22.6 22.9 23.6 22.3 22.8 22.6 23.2   
AGE effect 
on CL 
 0.107 0.119 0.114 0.106 0.117 0.140 0.111 0.119  
    95% CI      
  Mean SD lower upper      
ktr  7.84 0.131 7.78 7.91      
CL/F  28.1 1.26 27.5 28.7      
VC/F  58.6 2.06 57.6 59.5      
Vp/F  216 21.8 205 226      
Q/F  23.1 0.407 22.9 23.3      
AGE effect 
on CL 
 0.117 0.0178 0.109 0.126      
ktr = transfer rate constant between the sequential compartments, CL/F = apparent clearance, VC/F = volume of 
the central compartment, VP/F = volume of peripheral compartment Q/F = intercompartment clearance,  
F = bioavailability  
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3.4.3 Data splitting 
Figure 10 shows the parameter estimates for the full data set and for the 10 different subsets. 
All pharmacokinetic parameters estimates in the subsets, with exception of four estimates, 
were in the range of ± 2 SD of the final estimates. Moreover, the majority of the values were 
in the range of ± 1 SD.  
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Figure 10: Data splitting.  
Pharmacokinetic parameter estimates for the full dataset and the 10 subsets. Plots on the x-axis at value 0 are 
from the full dataset, and plots on the x-axis at values 1 to 10 are from the 10 subsets. The standard deviations 
(SDs) were calculated based on the Jackknife estimates.  
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The OFVs obtained by another NONMEM run for the full data set fixing the parameter 
estimates for the 10 subsets were in range from 2274.5 to 2275.4, which gives a non-
significant absolute difference from the final model (∆OFV = 0.9).  
 
3.4.3.1 Predictive performance (internal) 
In order to examine predictive performance of the final model, the NONMEM estimates from 
each of the 10 subsets were used to predict the concentration profiles in the remaining 10% of 
patients’ data. Individual AUC0-12 were calculated from the plasma concentration profiles 
using limited time measurements, and the result of bias (MPE) and prediction (MAPE) in 
each subset are presented in table 12. Without any information of the concentrations provided 
in the dataset, the mean absolute prediction error (MAPE) was 18.6%, which was due to over-
prediction of the observed concentrations (+8.5% bias). When using only one time sample, C0 
or C2, the prediction was reduced to about 10%. As expected, the prediction was better with 
two or three concentration measurements provided in the dataset. 
 
Table 12: Predictive performance in the subset groups.  
Subset No info C0 C2 C0+C2 C1+C2 C0+C1+C2 C0+C1+C3 
1 33.9 27.7 22.1 25.1 16.5 21.7 11.6 
2 24.3 9.2 22.5 11.9 15.0 4.7 7.2 
3 34.2 4.9 4.0 -4.9 -0.1 -5.0 -2.3 
4 32.6 13.9  -0.4 3.0 5.3 2.2 16.4 
5 10.5 17.0 0.8 10.8 2.4 11.5 7.2 
6 -8.2 -10.8  -7.8 -4.7 -0.4 -0.2 2.8 
7 -12.2 2.4 -11.4 0.05 -7.2 4.5 5.6 
8 -1.1 -1.7  -5.3 -2.8 -7.8 -6.3 -2.0 
9 -20.1 -13.4  -8.7 -10.3 -4.3 -7.4 -0.04 
10 -9.2 -8.4 -20.8 -13.0 -17.0 -13.0 -5.2 
MPE (%) 8.5 4.1 -0.5 1.5 0.2 1.3 4.1 
95% CI -4.7 – 13.2 -4.1 – 8.2 -9.1 – 8.6 -5.6 – 7.2 -6.2 – 6.4 -5.0 – 6.3 -0.2 – 4.2  
MAPE (%) 18.6 10.9 10.4 8.7 7.7 7.6 6.1 
MPE = mean prediction error, MAPE = mean absolute prediction error 
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3.4.4 External validation with Bayesian procedure 
The pharmacokinetic values from the final population model were used as priors for a MAP 
Bayesian estimator of individual pharmacokinetic parameters, based on limited-sampling 
strategy. The individual predicted AUC0-12 is presented in table 13, with mean bias (MPE) and 
prediction (MAPE) for the 10 new patients.  
 
Table 13: Bayesian AUC0-12 (µg/L*h) estimates using different sampling times compared to observed AUC0-12 
(µg/L*h). 
  OBS  No info C0 C2 C0+C2 C1+C2 C0+C1+
C2 
C0+C1+
C3 
Patient A 7408 8456 7170 8227 7362 8107 7166 7193 
Patient B 8749 9892 9746 7624 8907 8012 8778 9450 
Patient C 9029 11197 10260 9335 9719 9568 9408 9237 
Patient D 10358 8111 8282 10085 8960 10944 9678 10920 
Patient E 7255 7919 6192 9329 7351 7351 7535 7002 
Patient F 6865 10903 8129 7989 7246 8158 6936 7084 
Patient G 6147 8510 6423 7723 6484 7635 6126 6827 
Patient H 5437 6301 4760 4969 4331 4693 4392 5364 
Patient I 9646 13207 9615 9847 8725 10536 8070 8790 
Patient J 6232 6349 6242 6861 6456 6538 6277 6315 
MPE (%) 19.1 -0.3 7.3 -1.9 5.8 -3.7 1.5 
95% CI   5.3 – 12.8 -8.1 – 7.6 -1.2 – 15.8 -7.7 –4.0 -1.2 –12.7 -8.6 - 1.5 -2.2 - 5.2
MAPE (%) 23.4 9.9 12.1 7.0 10.2 5.6 4.4 
OBS: Observed AUC0-12 , MPE = mean prediction error, MAPE = mean absolute prediction error 
 
The mean prediction error (MPE) and mean absolute prediction error (MAPE) were in 
accordance with the predictive performance from the datasplitting analysis. The MAPE was 
23.4% without any concentrations given in the dataset. As in the data splitting analysis, this 
was due to over-prediction of the observed concentrations (+19% bias). When only C0 
concentration was provided the MAPE error was reduced to about 10%, which was slightly 
smaller than using C2 (12%). Providing the model with both C0 and C2 reduced the MAPE to 
7%, with low bias (-1.9%). The use of C1 and C2 did not give any notably reduction in MAPE 
compared to using only one time measurement. However, the plot of observed concentrations 
versus individual predicted concentrations (figure 11) showed good correlation (r2=0.956), 
which was better than using C0+C2 and even better than C0+C1+C3. The prediction in 
individual AUC0-12 was improved when using three time measurements, and the observed 
concentrations correlated well with the individual predicted concentrations. The coefficient of 
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determination (r2) was about the same in the plots of observed versus predicted concentrations 
(figure 11) using none concentrations or C0/C2.  
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Figure 11: Scatter plots of the concentrations predicted using different Bayesian estimators versus the 
observed concentration in the external patient group. 
Line of identity (——). 
RESULTS 
   
 
50 
3.5 NON-POPULATION ANALYSES  
The mean pharmacokinetic parameter estimates from the non-compartmental analysis and the 
WinNonlin analysis are presented in table 14.  
 
Table 14: Pharmacokinetic estimates from non-compartment and WinNonlin analysis  
Non-compartment WinNonlin 
CL/F (L/hrs) %CV Vd/F (L) %CV CL/F (L/hrs) %CV Vd/F (L) %CV 
23.4 37.2 254 65.3 11.6 59.8 243 103 
CL/F = apparent clearance, Vd/F = apparent distribution volume, F = bioavailability, CV = coefficient of 
variation 
 
 
WinNonlin was not able to analyze the concentration-time profiles for three of the patients 
when using the 2-compartment model with a lag-time from the library in WinNonlin (patient 
11, 14 and 34). The absorption phase was also poorly described.   
 
3.5.1 Comparison between non-compartment analysis, WinNonlin and NONMEM 
The individual estimates of CL/F and Vd/F for the three different methods was compared 
using SPSS. The statistical analysis in SPSS showed a significant difference between the three 
methods in estimating clearance, but not in estimating distribution volume (table 15).  
 
The difference between WinNonlin and NONMEM in calculating means of Vd/F was 35%, 
and the difference between non-compartment analysis and NONMEM was 32%. The 
difference between non-compartment and WinNonlin was only 4.2%. In the calculation of 
mean CL/F, there were a difference of 49% between WinNonlin and NONMEM. The 
difference between non-compartment and NONMEM was 7.4%. In contrast to estimation of 
Vd/F, the difference was high between the non-compartment and WinNonlin analysis for the 
estimation of mean CL/F (50%). 
 
Table 15: P-values from the statistic tests  
 CL/F (L/hrs) Vd/F (L) 
P-value <0.05 0.168 
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4 DISCUSSION 
4.1 POPULATION MODELS 
As described in section 1.4.8, one-, two-, and three compartment models have successfully 
been used to fit CsA datasets. Which model that best fits the data, may largely depend on the 
number of patients (and blood samples) in the population. As a general rule, at least one blood 
sample per patient per parameter (thetas, omegas and sigmas) is needed to be able to describe 
all the parameters in a model. 
 
In all the 1-compartment models tested, NONMEM was not able to describe the highest 
observed concentrations, and in the elimination phase the concentrations were over-
predicated. The diagnostic plot of WRES versus time showed a u-shaped curve, indicating 
bias in the model, which is indicative of model misspecification. The reason for the bias is the 
poor description of the distribution phase in a 1-compartment model, since CsA is highly 
lipophilic and therefore accumulates in fat-rich tissues [33]. Addition of a peripheral 
compartment improved the accuracy, reduced OFV and residual error. There is however 
studies that have chosen a 1-compartment model to fit CsA data [60, 61], but none of these 
studies reports wheter other compartment models have been evaluated. 
 
The 2-compartment models tested (with exception of the model with zero order absorption) 
showed high correlations between observed and predicted concentrations, as shown in figure 
5. The 3-compartment model with lag-time was highly sensitive for the initial parameter 
estimates. This is most likely due to a low number of patients (and blood samples) in 
proportion to number of parameters in a 3-compartment model. Moreover, the value of V3 
was unlikely high. However, the predicted concentrations correlated well with the observed 
concentrations, and OFV and residual error were similar to the best 2-compartment models.  
 
Based on the aspects above, a 2-compartment model for CsA seems to be a reasonable 
approximation for describing the pharmacokinetics of CsA. A more data-rich population is 
probably necessary if a 3-compartment model would be used to fit the data. Even though the 
OFV was significant better with the 2-compartment model, it is unknown whether the 3-
compartment model reached its minimum OFV or not, since this model was highly unstable. 
Therefore, the effect of an additional peripheral compartment can not be completely 
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evaluated. A study by Fanta et al. found that a 3-compartment model best described the 
pharmacokinetics of CsA in a dataset consisting of 162 children (approximately 10 samples 
per patient) [64]. However, a study by Saint-Marcoux et al. including almost the same number 
of patients (147) and same number of samples per patient found that a 2-compartment model 
best described the CsA pharmacokinetics [63]. The in-consistent reporting on the best 
compartment model for CsA indicates that both a 2-compartment and a 3-compartment model 
may describe the pharmacokinetics of CsA.  
 
The absorption profile of CsA is characterized by a lag-phase followed by rapid absorption, 
which also was present in the concentration-time profiles of the patients studied in this thesis 
(figure 2). The absorption phase was poorly described in the models that did not account for a 
delay in the absorption (figure 5). The concentrations were over-predicted in the beginning of 
the absorption phase, followed by an under-prediction of the concentrations around Cmax. 
NONMEM assumes rapid absorption when no lag-time is present in the model, and as a 
consequence of this over-prediction in the beginning of the absorption the concentrations 
around Cmax is under-predicted. The fit around Cmax was better when the absorption phase was 
adequately described.  
 
A zero order rate constant did not describe the absorption of CsA, which may indicate that the 
absorption of CsA is dependent of the amount of drug remaining to be absorbed. However, 
Bourgoin et al. reported a model with zero order absorption (and lag-time) to best describe the 
CsA dataset [62], and both zero- and first- order absorption kinetics were evaluated in this 
study. There is, however, a main emphasis for using first order absorption kinetics to describe 
the pharmacokinetics of CsA [60, 61, 64]. 
 
Including lag compartments (Erlang distribution) in the absorption phase gave a better fit of 
the CsA data than a classical zero- or first-order rate constant connected with a lag-time 
parameter. Even though the change in OFV was not significantly lower compared to the 2-
compartment model with first order absorption and lag-time, the 2-compartment model with 
Erlang distribution was more robust. The estimates of the pharmacokinetic parameters in the 
2-compartment model with Erlang distribution did not change significantly when changing 
the initial estimates, while the estimates in the other models were highly unstable. This is 
probably a result of the greater flexibility of the model with Erlang distribution when 
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modeling flat/delayed absorptions profiles. Previous studies have also proposed models 
including serial lag compartments (Erlang distributions) to predict highly variable absorption 
processes [63, 66, 81], demonstrating an advantage in such a model when modeling 
flat/delayed absorption. Furthermore, the 2-compartment model with Erlang distribution 
required estimation of 5 pharmacokinetic parameters (CL, Q, Vc, Vp and ktr) compared with 6 
parameters for the 2-compartment model with lag time (CL, Q, Vc, Vp, ka and lag time). This 
difference is important considering the fact that the more parameters in the model the more 
samplings times are required.  
 
The average values of the pharmacokinetic parameters obtained in this thesis were similar to 
those published in previously studies in renal transplant patients using a 2-compartment 
model with Erlang distribution to describe the absorption phase [63, 66, 81]. In addition, the 
average values of the parameters were close to those previously published using a 2-
compartment model without Erlang distribution [62, 65].  
 
The estimated interindividual variability is a measure of the unexplained random differences 
between individuals, and the mean values of the interindividual variability in this thesis were 
consistent with previous results. Interindividual variability in CL/F, Q/F, Ktr and VC/F was 
moderate, whereas interindividual variability in VP/F was high (95.6%). However, the high 
interindividual variability in VP/F is comparable to previously reports. Hesselink et al. 
reported an interindividual variability in VC/F of 128% [65], Saint-Marcoux et al. reported an 
interindividual variability in VP/F of 80% [63] and Fanta et al. reported an interindividual 
variability in VC/F of 124.4% [64]. 
 
Residual variability represents the uncertainty in the relationship between the blood 
concentrations predicted by the model and the observed concentration. Modeling residual 
variability as a combination of additional and proportional error model gave the values 37.6 
µg/L and 13.5% respectively. These findings are in accordance with previously work [60, 63, 
66]. Correct measurement of the magnitude and structure of the residual error may be 
important if the model is to be used as prior information for subject-specific Bayesian 
estimation. However, there is difficult to evaluate which error model that describes the 
residual variability of the data best, since the true value of the residual error is not known.  
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Predicted (PRED) and individual predicted (IPRED) concentrations versus observed (OBS) 
concentrations were randomly distributed around the line of identity, and did not show any 
clear bias (figure 7). This indicates that the model works, with no suggestion of model 
misspecification. The correlation (r2) was better between IPRED and OBS than between 
PRED and OBS. This is because IPRED are based on individual models for each patient, in 
stead of mean parameter values calculated for the whole population.  
 
The scatterplot of weighted residual error (WRES) versus time were uniform spread without 
any trend (figure 7). The scatterplot of WRES versus ID showed an indication of an outlier. 
This patient (ID number 10) had an observed concentration of 3766 µg/L, which is higher 
than the standard curve in the method used for analysing CsA concentrations [82]. Therefore, 
the large WRES in this patient may be due to higher variation in the whole blood analysis of 
this concentration. 
 
 
4.2 COVARIATE ANALYSIS 
The different population analyses of CsA using NONMEM report different covariates for 
significant influence on the pharmacokinetic parameters. Low number of patients included in 
a study may hinder proper statistics, as may be the case in this thesis. However, a study by 
Kyhl et al. including 728 stable kidney transplant patients [83] showed no effect of age, 
gender, dose, height, days since transplantation or weight on the pharmacokinetics of CsA. 
These findings suggest that other factors, like genetic polymorphism, may contribute to 
variability in CsA pharmacokinetics. The association between genetic factors in the 
metabolic-and transport enzymes and absorption/ clearance of CsA has been investigated [65, 
84-87]. However, no clear differences were demonstrated in these studies, even though a 
tendency for a correlation between the expression of CYP3A5*1 and higher metabolism was 
observed. Haufroid et al. [86] and Hu et al. [87] reported higher dose-adjusted trough 
concentrations (C0) in patients expressing the CYP3A5*1, which is expressed in the liver of 
approximately 20% of the population [88]. Further studies are needed to explore this 
relationship. In this thesis, none of the patients expressed the CYP3A5*1 allele, so the 
relationship could therefore not be examined.  
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Age as a covariate on CL/F was the only covariate that gave significant lower OFV. CsA is 
primarily eliminated via cytochrome P450(CYP)3A biotransformation in the liver and small 
intestine [26, 30]. No age-related decrease in the CYP3A activity has been reported either in 
vitro or in vivo [89]. By contrast, a significant fall in liver mass and liver blood flow with age 
has been documented [90]. For a drug with high clearance intrinsic, like CsA, the effect of age 
on elimination is therefore expected. The interindividual variability in clearance was not 
reduced notably when including age as a covariate for clearance, which may indicate that the 
effect of age was slightly. However, the interindividual variability in the peripheral 
distribution volume (VP/F) was reduced from 110% to 96%.  
 
Body weight during CsA treatment is an important aspect, since many patients gain weight 
after transplantation. The increase in body weight is due to re-establishing an anabolic state 
and administration of high-dose steroid. Previous works have found an effect of body weight 
on distribution volume (Vd/F) [60, 61, 91]. Introducing body weight as a covariate on Vd/F 
gave a non-significant reduction in OFV. Moreover, the interindividual variability in 
distribution volume (Vd/F) was not reduced when adding weight as a covariate on Vd/F; in 
fact it was increased by 2.5%. However, the small number of patients may have hindered 
proper statistical evaluation. In addition, the range in body weight was low [68-97], with a SD 
of 9 kg, which may have further contributed to a non-significant result.  
 
The lack of significant influence from estimated creatinine clearance on CsA is logical 
considering that CsA is primarily eliminated by metabolism [26, 30], which means that 
decreased renal function does not affect its pharmacokinetics considerably.  
 
It has been demonstrated in studies that diabetics have a slow and erratic absorption of CsA, 
with more intrapatient variability in C2 [75]. Four of the patients in this thesis were diabetic. 
By visual examinations of the concentration-time curves, only one of these patients showed 
an indication of a more slow absorption. In this thesis the patients with diabetes did not show 
a relevant slower absorptions profile. The estimated transfer constant (ktr) for the diabetic 
patients was 7.84, compared to 7.87 in non diabetic patients. However, the number of diabetic 
patients was too small to give any significant differences, although there was a tendency of no 
difference between diabetic and non-diabetic patients with regards to absorption. 
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When modeling slow absorptions profile using the mixture function, NONMEM placed only 
one patient in the subpopulation with slower absorption (lower ka). Interestingly, this patient 
was non-diabetic. The very slow absorption of this patient is suspected to be due to eating 
prior to CsA morning dose. However, this aspect is important for further investigation in 
order to improve the model; can another covariate be added to the model to better describe the 
slow absorption? 
 
Previous work has reported that the value of CL/F decline after transplantation, especially 
within the 3 first weeks [60, 91]. The mean post-transplantation period for patients studied 
here were 5.5 weeks [2.1-10.4], with only 3 patients within the 3 first weeks after 
transplantation. From the graphical analysis, CL/F showed an indication of a higher value 
within the 3 first weeks (appendix). In the studies reporting a decline in CL/F after 
transplantation more patients and a wider range in post-transplantation period were present. If 
more patients within the 3 first weeks after transplantation were included in the dataset, a 
time-related clearance could perhaps improve the model. 
 
Konishi et al. have demonstrated that treatment with steroid (methylprednisolone sodium 
succinat) significantly increased the total body clearance of intravenously administration of 
CsA by induction of hepatic CYP3A [92]. In addition, systemic bioavailability of CsA after 
oral administration were shown to be markedly reduced by steroid dosing, and the mechanism 
of interaction was confirmed to involve enhancement of P-gp and decrease in bile secretion 
[93]. The effects of steroid dose are more prominent the first time after transplantation, since 
dosing of steroid are higher initially. No clear relationship was found in this thesis. However, 
an indication of a higher clearance associated with a 20 mg dose of steroid at the 
pharmacokinetic day compared to 10 mg dose was seen (appendix). 
 
Gender had no effect on any of the pharmacokinetic parameters. No clear relationships were 
seen in the graphical covariate analysis (appendix). It has been shown that females have a 
higher CYP3A activity than males [94], which could result in higher clearance of CsA in 
females. In fact, the tendency was opposite here; a slightly higher clearance for men was seen 
in the graphical analysis (appendix). However, this incompatible relationship is probably 
caused by a low number of females (6/17), and was therefore not tested any further. The 
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effect of height was also insignificant, which was not surprising considering the fact that 
weight did not influence the distribution volume in this thesis.  
 
4.3 VALIDATION 
The posterior predictive check method gives an initial quantitative validation of the model. 
The result did not give any suspicion of model misspecification, since the 95% CI of Cmax, 
Ctrough and AUC0-12 from the 100 simulations contained the mean of the “true” values. In 
addition, the paired statistic test showed no significant differences between observed and 
simulated values of Cmax, Ctrough and AUC0-12.  
 
A data splitting analysis was further applied. This approach is recommended by the US Food 
and Drug Administration (FDA) [7]. The pharmacokinetic parameter estimates in the subset 
groups were not significantly different from those obtained from the whole data set, which 
indicates that no subsets of the population had high influence on the estimation of the 
pharmacokinetic parameters. Moreover, the OFVs obtained by another NONMEM run for the 
full data set fixing the parameter estimates for the subsets were not significant different from 
the OFV in the final model (∆OFV = 0.9). The data splitting analysis confirmed the 
robustness of the final model. 
 
The predictive performance of the 10% of patients excluded in each of the 10 subset groups 
showed a good prediction of individual AUC0-12. Predicting AUC0-12 using the population 
model with individual dose and age provided, resulted in an absolute error in prediction of 
18.5%, which is relative low considering the limited information given (dose and age). In 
addition, this result is in agreement with a data splitting analysis for CsA performed by Saint-
Marcoux et al., which reported a mean absolute prediction error (MAPE) of 18% [63]. Irtan et 
al. studied pharmacokinetics of CsA in pediatric renal transplant patients, and found a MAPE 
of 29.4% in a data splitting procedure [81]. When including one time measurement (C0 or C2), 
the prediction error was reduced to an average of 10.5%, with no clear difference between C0 
and C2. As expected, the predictions were better when including two or three measurements 
within the absorption phase. These results demonstrate the good performance of the 
population model developed, which was further supported by testing the model in an external 
group. 
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The predictive performance in an external group consisting of 10 new kidney transplant 
patients was also tested. Providing the model with information about concentrations at 0, 1 
hour and 3 hour provided the best prediction of individual AUC0-12 (4.79%), which is in 
agreement with previously Bayesian estimation studies. Saint-Marcoux et al. reported a 
MAPE of 10.5% [63], Rousseau et al. reported a MAPE of 5.3% [66] and Leger et al. 
reported a MAPE of only 2% [95] when using a Bayesian estimator at times 0, 1 hour and 3 
hour. Bourgoin et al [62] selected times 0, 1 hour and 2 hour for Bayesian estimation, and 
found an accuracy of 13.1%.  
 
The purpose of Bayesian estimation is to apply it to AUC-based TDM of CsA, and therefore 
practicality is important. Using only one concentration-measurement provided, in clinical 
terms, good prediction of observed AUC. A MAPE of approximately 10% was observed 
using C0, while the MAPE was approximately 12% when using C2. A MAPE of 10-12% 
should not have important clinical consequences, with respect to proposed therapeutic range 
for CsA. Mahalti et al. suggest a target AUC0-12 in kidney transplant patients in the range of 
9500-11500µg*h/L during the first period after transplantation [96]. However, target AUC 
may differ according to different authors. 
 
External validation is the most stringent test of a model. Bayesian method using limited blood 
samples allowed a precise estimation of AUC0-12 in a population of 10 kidney transplant 
recipients. In addition, the results in the external group were in agreement with the internal 
validation method. However, for clinical purposes, the model should be able to predict 
individual AUC0-12 the day after the time measurement(s). 
 
4.4 NON-POPULATION ANALYSES 
A WinNonlin analysis and non-compartment calculation in Excel were performed to elucidate 
whether there were significant differences between the parameter estimates obtained in these 
methods and the NONMEM analysis. The result showed a significant difference in estimating 
CL/F, but not in Vd/F. However, the large variation seen in Vd/F (22–1212L) makes it 
difficult to truly evaluate statistic significant differences. An interesting finding was that non-
compartment calculations were closer to the NONMEM analysis in estimating Vd/F and CL/F 
compared to the WinNonlin analysis. 
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Regardless of significant differences in parameter estimates or not, population analysis 
(NONMEM) has advantages over the two other methods in estimating variability, considering 
variance of point estimates and allowing formal testing of covariates. The variance of point 
estimates are important, especially if the data set are small and simultaneously contains 
outliers. In addition, Bayesian approach diminishes importance when not doing a population 
analysis as performed with NONMEM.  
 
The WinNonlin analysis would have been more valuable if it were performed before the 
NONMEM analysis. WinNonlin results can serve as indication of initial parameter estimates 
for the population modeling. In addition, individual modeling in WinNonlin can give a good 
suggestion for the most likely compartment model for the dataset. 
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5 CONCLUSION AND FUTURE CONSIDERATIONS 
The main aim for this thesis was to develop a pharmacokinetic population model for CsA, 
which in the future can be used as a Bayesian prior when designing dosing regimens for new 
kidney transplant recipients. 
 
In order to find the best pharmacokinetic population model, different compartment models 
with different absorption profiles were examined. From the different models tested, it can be 
concluded that a 2-compartment model with Erlang distribution to describe the absorption 
phase provided the best fit of the CsA data set.  
 
In the screen for patient covariates that could describe some of the interindividual variability 
in the pharmacokinetic parameters, it can be concluded that age was a significant covariate for 
clearance. However, there is reason to believe that the data set used for this purpose was too 
sparse for other covariates to reach statistic significance. A re-run of the covariate analysis 
including more patients is therefore needed.  
 
Finally, the model was also validated with both internal and external methods. The results 
indicated that the pharmacokinetic population model developed is robust and that the model is 
able to predict individual AUC0-12 in new kidney transplant patients using limited 
concentration measurements, with no clear differences from the internal validation method. 
However, more patients included in the dataset would confirm the predictive performance of 
the population model. Furthermore, the model should be able to predict individual AUC0-12 
the day after the time measurement(s) for practical use in clinical settings. For this purpose, 
prior dose history needs be included in the dataset when developing the pharmacokinetic 
population model and the effect of inter-occasion variability should be evaluated.  
 
In conclusion, a 2-compartment model with Erlang distribution as an absorption process and 
age as a covariate provides a good basis for the development of a model that can be used to 
optimize dosing regimens in new kidney transplant patients. 
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7 APPENDIX 
7.1 Input file for building the population model 
ID AMT RATE TIME CON WT CRCL MDV SS II CMT FLAG AGE GENDER HEIGHT TXT STER
7 100000 0 0 0 70.2 43 1 2 12 1 1 60 2 1.65 9 10
7 0 0 0 380 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 0.23 451 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 0.58 775 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 1.13 1639 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 1.62 2063 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 2.07 1217 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 3.1 692 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 4.03 625 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 6.02 454 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 8.02 385 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 9.97 315 70.2 43 0 0 0 8 1 60 2 1.65 9 10
7 0 0 11.93 312 70.2 43 0 0 0 8 1 60 2 1.65 9 10
8 225000 0 0 0 90.3 95.2 1 2 12 1 1 59 1 1.85 4.1 20
8 0 0 0 383 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 0.23 274 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 0.48 764 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 0.98 1633 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 1.43 1941 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 1.98 1976 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 3.03 944 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 4.07 681 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 5.98 574 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 8.03 319 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 9.97 187 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
8 0 0 11.9 262 90.3 95.2 0 0 0 8 1 59 1 1.85 4.1 20
9 200000 0 0 0 75.7 53.5 1 2 12 1 1 33 2 1.8 7.6 20
9 0 0 0 227 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 0.12 180 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 0.45 334 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 0.97 1666 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 1.47 1452 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 1.95 1227 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 2.92 754 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 3.88 393 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 5.9 197 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 7.88 267 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
9 0 0 11.62 155 75.7 53.5 0 0 0 8 1 33 2 1.8 7.6 20
10 150000 0 0 0 67.6 52.5 1 2 12 1 1 35 1 1.85 4.6 15
10 0 0 0 260 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 0.3 273 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 0.52 690 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 0.98 2766 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 1.48 3766 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 2.02 2402 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 3 1748 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 3.95 1461 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 5.88 590 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
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10 0 0 7.92 428 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 9.9 314 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
10 0 0 11.88 267 67.6 52.5 0 0 0 8 1 35 1 1.85 4.6 15
11 200000 0 0 0 75.3 81.2 1 2 12 1 1 52 1 1.88 4.4 20
11 0 0 0 364 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 0.3 313 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 0.57 371 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 1 2575 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 1.52 2084 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 2.03 1690 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 2.97 1522 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 3.95 1001 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 5.97 524 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 7.87 552 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 9.95 407 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
11 0 0 11.75 359 75.3 81.2 0 0 0 8 1 52 1 1.88 4.4 20
12 225000 0 0 0 96.7 72.2 1 2 12 1 1 67 1 1.81 4.3 15
12 0 0 0.25 510 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 0.48 942 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 1.18 1669 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 1.65 1830 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 2.17 1732 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 3.18 864 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 4.13 711 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 6.13 622 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 8.08 415 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 10.02 377 96.7 72.2 0 0 0 8 1 67 1 1.81 4.3 15
12 0 0 11.97 343 96.2 72.2 0 0 0 8 1 67 1 1.81 4.3 15
14 125000 0 0 0 68.7 92.7 1 2 12 1 2 60 2 1.72 6.3 15
14 0 0 0 257 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 0.2 261 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 0.48 389 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 1.07 2398 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 1.55 1709 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 2 1492 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 3 919 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 3.97 624 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 5.95 488 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 8 312 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 10.03 246 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
14 0 0 11.73 178 68.7 92.7 0 0 0 8 2 60 2 1.72 6.3 15
18 125000 0 0 0 74.1 54.8 1 2 12 1 1 74 1 1.64 3.1 20
18 0 0 0 325 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 0.25 285 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 0.53 460 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 1.13 1888 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 1.6 2299 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 2.07 1391 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 3.05 884 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 4.03 564 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 6 384 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 8.08 301 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 10.12 239 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
18 0 0 11.8 205 74.1 54.8 0 0 0 8 1 74 1 1.64 3.1 20
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19 350000 0 0 0 79.9 63.5 1 2 12 1 2 52 1 1.76 2.1 20
19 0 0 0 340 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 0.23 366 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 0.48 343 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 1.08 1814 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 1.55 1923 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 2.05 1480 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 3.03 1192 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 4.02 953 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 5.98 782 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 8.1 462 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 10.1 435 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
19 0 0 11.78 407 79.9 63.5 0 0 0 8 2 52 1 1.76 2.1 20
30 150000 0 0 0 91.5 75.3 1 2 12 1 1 25 1 1.82 9.3 10
30 0 0 0 153 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 0.5 247 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 1.03 783 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 1.52 1041 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 2.02 1266 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 2.52 939 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 3.05 825 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 4.25 474 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 4.97 355 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 6.03 259 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 7.98 215 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 9.98 157 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
30 0 0 11.9 126 91.5 75.3 0 0 0 8 1 25 1 1.82 9.3 10
31 125000 0 0 0 78 74.1 1 2 12 1 1 61 2 1.7 10.4 20
31 0 0 0 346 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 0.6 1104 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 1.2 1743 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 1.52 1408 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 2 994 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 2.53 718 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 3.02 580 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 4.05 428 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 4.97 392 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 6.03 294 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 8.07 276 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 10.07 269 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
31 0 0 12.02 263 78 74.1 0 0 0 8 1 61 2 1.7 10.4 20
32 150000 0 0 0 90.8 86.7 1 2 12 1 2 59 1 1.79 9 20
32 0 0 0 173 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 0.48 287 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 1.08 1165 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 1.53 1782 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 2.07 1169 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 2.53 1095 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 3.03 1028 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 4 639 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 5.02 526 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 6.03 445 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 7.98 373 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
32 0 0 9.98 319 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
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32 0 0 11.68 316 90.8 86.7 0 0 0 8 2 59 1 1.79 9 20
33 175000 0 0 0 78 69.4 1 2 12 1 2 68 2 1.56 3 20
33 0 0 0 317 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 0.5 1260 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 1 2492 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 1.53 2046 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 2 1862 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 2.55 1413 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 3.02 1217 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 3.97 787 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 5.02 739 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 6 585 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 8.05 543 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 10 487 78 69.4 0 0 0 8 2 68 2 1.56 3 20
33 0 0 11.53 404 78 69.4 0 0 0 8 2 68 2 1.56 3 20
34 125000 0 0 0 85.7 66.2 1 2 12 1 1 69 2 1.64 6.9 15
34 0 0 0 367 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 0.57 1235 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 1.05 2387 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 1.53 1801 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 2.02 1000 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 2.53 829 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 3.03 613 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 3.98 633 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 4.97 552 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 6.02 376 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 8.03 310 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 10 329 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
34 0 0 11.95 341 85.7 66.2 0 0 0 8 1 69 2 1.64 6.9 15
35 250000 0 0 0 80 100.4 1 2 12 1 1 23 1 1.8 4 15
35 0 0 0 348 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 0.5 354 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 1.03 609 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 1.55 1175 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 2.05 1530 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 2.55 1760 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 3.1 1406 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 4.03 1034 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 5 815 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 6 575 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 8 383 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 9.98 333 80 100.4 0 0 0 8 1 23 1 1.8 4 15
35 0 0 11.93 247 80 100.4 0 0 0 8 1 23 1 1.8 4 15
36 125000 0 0 0 86.4 76.8 1 2 12 1 1 52 1 1.89 3 20
36 0 0 0 117 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 0.48 460 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 0.98 1313 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 1.5 1583 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 1.97 797 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 2.52 505 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 3.02 450 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 4.05 335 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 5 231 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 5.98 170 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
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36 0 0 7.98 151 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 9.98 103 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
36 0 0 11.77 285 86.4 76.8 0 0 0 8 1 52 1 1.89 3 20
37 125000 0 0 0 85.6 74.9 1 2 12 1 1 59 1 1.89 3.3 20
37 0 0 0 190 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 0.5 848 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 1.02 2027 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 1.5 1690 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 1.98 1474 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 2.55 813 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 3.03 784 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 4.08 548 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 5 508 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 6.02 399 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 8.02 338 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 10 289 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
37 0 0 11.8 216 85.6 74.9 0 0 0 8 1 59 1 1.89 3.3 20
 
 
 
7.2 Individual fits in the final pharmacokinetic model 
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7.3 Covariate analysis 
 
  
 
 
CL/F 
Vd/F 
Q/F 
Vp/F 
 
CL/F 
Vd/F 
Q/F 
Vp/F 
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7.4 Control file for the 1-compartment model with lag-time 
 
$PROBLEM 1-compartment firs order absorption with lagtime  
 
$DATA CsA.pasienter.txt 
 
$INPUT ID AMT RATE TIME C=DV MDV SS II 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK 
CL = THETA(1)*EXP(ETA(1))  
V = THETA(2)*EXP(ETA(2)) 
KA = THETA(3)*EXP(ETA(3))  
ALAG1 = THETA(4)*EXP(ETA(4))  
 
S2 = V  
 
$ERROR 
IPRED=F 
Y=F+F*ERR(1)+ERR(2)  
 
$THETA  
(1, 20)   
(10,114)  
(0.1, 1)  
(0.1, 0.45)  
 
$OMEGA BLOCK (3) 
0.097            
0.1   0.12        
0.05  0.006  0.2   
 
$OMEGA 
0.02 
 
$SIGMA 0.01 ;ERRCV 
$SIGMA 10 ;ERRSD 
 
$ESTIMATION METHOD=1 INTER MAXEVAL=9999 PRINT=1 POSTHOC 
 
$COVARIANCE 
 
$TABLE ID TIME DV IPRED  
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID V CL ETA1 ETA2  
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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7.5 Control file for the 2-compartment model with first order absorption and a lag-
time 
 
 
 
 
 
$PROB 2-compartment first order absorption with a lag-time 
 
$DATA InputfilMEDkovariater.txt 
 
$INPUT ID AMT RATE TIME CON=DV WT CRCL MDV SS II FLAG AGE SEX 
 
$SUBROUTINE ADVAN4 
 
$PK ; Define basic PK relationships 
CL=THETA(1)*EXP(ETA(1))  
V1=THETA(2)*EXP(ETA(2))  
Q=THETA(3)*EXP(ETA(3))  
V2=THETA(4)*EXP(ETA(4))  
KA=THETA(5)*EXP(ETA(5)) 
ALAG1=THETA(6)*EXP(ETA(6))  
 
S2=V1  
 
K=CL/V1 
K23=Q/V1 
K32=Q/V2 
 
$ERROR 
IPRED=F 
Y=F+F*ERR(1)+ERR(2 
 
$THETA  
(10,21)  
(10,43)  
(10,23.5)  
(10,214,1000)  
(0.1,1.52)  
(0.1,0.45 
 
$OMEGA BLOCK(6) 
0.074                         
0.002 0.068                      
0.002 0.002 0.0242                  
0.0001 0.0001 0.0001 0.001               
0.002 0.002 0.002 0.002 0.0339           
0.002 0.002 0.002 0.002 0.002  0.011      
 
$SIGMA 0.1 ;ERRCV 
$SIGMA 10 ;ERRSD 
 
$ESTIMATION NOABORT METHOD=1 INTER MAXEVAL=9999 PRINT=5 POSTHOC ; 
FOCE method 
 
$COVARIANCE 
 
$TABLE ID TIME DV IPRED 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID V1 V2 CL Q WT CRCL AGE SEX ETA1 ETA2 ETA3 ETA4 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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7.6 Control file for the 2-compartment model with zero order absorption and a lag-
time 
 
 
 
$PROB 2-compartment zero order absorption and a lagtime 
 
$DATA Inputfil.txt 
 
$INPUT ID AMT RATE TIME CON=DV MDV SS II 
 
$SUBROUTINE ADVAN3  
 
$PK  
  CL=THETA(1)*EXP(ETA(1))  
  V1=THETA(2)*EXP(ETA(2))  
  Q=THETA(3)*EXP(ETA(3))  
  V2=THETA(4)*EXP(ETA(4))  
  Ka=THETA(5)*EXP(ETA(5)) 
  ALAG1=THETA(6)*EXP(ETA(6))  
 
  S2=V1 
 
  K=CL/V1 
  K12=Q/V1 
  K21=Q/V2 
 
$ERROR 
  IPRED=F 
  Y=F+F*ERR(1)+ERR(2)  
 
$THETA (1,10)     
$THETA (1,1)    
$THETA (1,10)    
$THETA (10,50)     
$THETA (0.1,0.32)     
$THETA (0.1,0.45)  
 
$OMEGA  
0.01                         
0.01                      
0.01                  
0.01               
0.01            
0.01       
 
$SIGMA 0.025  
$SIGMA 1  
 
$ESTIMATION SIG=4 MAX=9999 PRINT=1 METHOD=1 INTER POSTHOC  
 
$COVARIANCE 
 
$TABLE ID TIME DV IPRED 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID V1 V2 CL Q ETA1 ETA2 ETA3 ETA4 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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7.7 Control file for the 3-compartment model with lag-time 
 
 
$PROB Three Compartment first order absorption with a lagtime 
 
$DATA InputfilMEDkovariater.txt 
 
$INPUT ID AMT RATE TIME CON=DV WT CRCL MDV SS II FLAG AGE SEX 
 
$SUBROUTINE ADVAN12  
 
$PK ; Define basic PK relationships 
  NCMT = 3 
  CL=THETA(1)*EXP(ETA(1))   
  V1=THETA(2)*EXP(ETA(2))   
  CLRA=THETA(3)*EXP(ETA(3))   
  V2=THETA(4)*EXP(ETA(4))   
  CLSL=THETA(5)*EXP(ETA(5))   
  V3=THETA(6)*EXP(ETA(6))      
  KA=THETA(7)*EXP(ETA(7))  
  ALAG1=THETA(8)*EXP(ETA(8))  
   
  S2=V1 
   
  K=CL/V1 
  K23=CLRA/V1 
  K24=CLSL/V1 
  K32=CLRA/V2 
  K42=CLSL/V3 
 
$ERROR 
  IPRED=F 
  Y=F+F*ERR(1)+ERR(2) 
 
$THETA  
(10,20.5)     
(10,43)     
(10,10.1) 
(10,20)   
(1,15.3)  
(10,605,10000) 
(1,1.45)     
(0.1,0.45)  
 
$OMEGA BLOCK(6)  
0.074                                
0.002 0.068                             
0.002 0.002 0.0242                         
0.0001 0.01  0.01  0.16                      
0.002 0.002 0.002 0.002 0.0339                  
0.002 0.002 0.002 0.002 0.002  0.0339              
 
$OMEGA 
0.1 ;BSVKA 
0.01 ;BSVALAG1 
 
$SIGMA 0.1 ;ERRCV 
$SIGMA 10 ;ERRSD 
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 $ESTIMATION METHOD=1 INTER MAXEVAL=9999 PRINT=1 
POSTHOC  
 
$COVARIANCE 
 
$TABLE ID TIME DV IPRED NCMT  
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID V1 V2 V3 CL CLRA CLSL WT CRCL AGE SEX ETA1 ETA2 
ETA3 ETA4 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
 
